Amblyopia Market

Market Overview:

The 7 major amblyopia markets reached a value of US$ 3.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.4 Billion by 2034, exhibiting a growth rate (CAGR) of 2.89% during 2024-2034.

The amblyopia market has been comprehensively analyzed in IMARC's new report titled "Amblyopia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Amblyopia, also known as "lazy eye," is a condition where the brain and eyes do not work together properly, leading to reduced vision in one or both eyes. It often begins in childhood with onset before the age of six. Amblyopia is characterized by various functional abnormalities in spatial vision, such as poor visual acuity, vernier acuity, contrast sensitivity function, spatial distortion, impaired contour detection, abnormal spatial interactions, etc. Individuals suffering from this disease may experience a tendency to bump into objects on one side as well as a wandering eye, poor depth perception, squinting or shutting an eye, head tilting, and double vision. The diagnosis of amblyopia is based on a thorough evaluation of the patient's symptoms and medical history. The healthcare professional may perform an eye examination to detect vision clarity, eye muscle strength, and eye focus. Additionally, a corneal light reflex test that checks for eye alignment by demonstrating light reflection from the cornea of the eyes is used to confirm the diagnosis.

The increasing prevalence of vision-obstructing disorders, such as refractive error and strabismus, is primarily driving the amblyopia market. In addition to this, the escalating usage of novel medications, including GABA antagonists and decarboxylase inhibitors, to improve visual acuity and visual-evoked potential amplitudes is further creating a positive outlook for the market. Moreover, the widespread adoption of digital imaging technologies, such as optical coherence tomography (OCT) and fundus photography, to diagnose amblyopia is also bolstering the market growth. These technologies can provide detailed images of the eye and allow for more accurate diagnosis and monitoring of the condition. Additionally, several government bodies are introducing screening programs, which involve visual acuity tests and other assessments in order to identify amblyopia in children at an early age. This, in turn, is acting as a significant growth-inducing factor. Furthermore, the increasing utilization of VR training for improving visual processing and coordination in amblyopic patients is also propelling the market growth. Besides this, the emerging popularity of patching coupled with binocular treatments, such as I-Bit, which improves best corrected visual acuity in the amblyopic eye, is expected to drive the amblyopia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the amblyopia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for amblyopia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amblyopia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the amblyopia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the amblyopia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current amblyopia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the amblyopia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the amblyopia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the amblyopia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of amblyopia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amblyopia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amblyopia by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amblyopia by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with amblyopia across the seven major markets?
• What is the size of the amblyopia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of amblyopia?
• What will be the growth rate of patients across the seven major markets?
   

Amblyopia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for amblyopia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amblyopia market?
• What are the key regulatory events related to the amblyopia market?
• What is the structure of clinical trial landscape by status related to the amblyopia market?
• What is the structure of clinical trial landscape by phase related to the amblyopia market?
• What is the structure of clinical trial landscape by route of administration related to the amblyopia market?